Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States
Record date: 2026-04-09
Proclamation 11020 of April 2, 2026 Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States A Proclamation 1. The Secretary of Commerce (Secretary) recently transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security of the United States under section 232 of the Trade Expansion Act of 1962, as amended, 19 U.S.C. 1862 (section 232). Based on the facts considered in that investigation, and taking into account the close relation of the economic welfare of the
What this record contains
- Federal Register document
- 2026-06956
- Publication date
- 2026-04-09
- Citation
- 91 FR 18183
- Issuing office
- Executive Office of the President
Official record excerpt
Proclamation 11020 of April 2, 2026 Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States A Proclamation 1. The Secretary of Commerce (Secretary) recently transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security of the United States under section 232 of the Trade Expansion Act of 1962, as amended, 19 U.S.C. 1862 (section 232). Based on the facts considered in that investigation, and taking into account the close relation of the economic welfare of the Nation to our national security and other relevant factors, see 19 U.S.C. 1862(d) , the Secretary found and advised me of his opinion that pharmaceuticals and associated active pharmaceutical ingredients (APIs), including key starting materials, are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States. 2. The Secretary found that the present quantities and circumstances of imports of pharmaceuticals and pharmaceutical ingredients threaten to impair the national security and economy. Despite being the world leader in research and development (R&D) for most innovative pharmaceuticals (those that are typically patented and branded, as compared to generic pharmaceuticals or pharmaceuticals approved pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(j) ), the United States is heavily reliant on imports, threatening to limit United States access to life-saving medications in the event of global supply chain disruption due to geopolitical or economic disruption. According to the Food and Drug Administration, as of 2025, approximately 53 percent of patented pharmaceutical products distributed domestically are produced outside the country. The degree of import reliance is significant at the API level with only 15 percent of patented APIs by volume domestically produced for the United States market. 3. The Secretary found that patented pharmaceuticals and associated pharmaceutical ingredients are essential to the United States' military and civilian healthcare. A self-sufficient domestic manufacturing and industrial base for pharmaceutical products is vital for the ability to support national defense requirements and maintain public health security during a national emergency or wartime. Patented pharmaceuticals are pivotal for treating cancer, rare diseases, autoimmune disorders, infectious diseases, and other critical health challenges. The Secretary further found that foreign government intervention has undermined the competitiveness of the United States patented pharmaceutical industry. This intervention has led to further dependence on foreign production of patented pharmaceuticals that have fragile supply chains. 4. In light of these findings, the Secretary recommended actions to adjust imports of patented pharmaceuticals and associated pharmaceutical ingredients, including continuing to negotiate onshoring agreements related to Most-Favored-Nation (MFN) pharmaceutical pricing agreements; imposing significant tariffs on pharmaceuticals and pharmaceutical ingredients, so that such imports will not threaten to impair the national security of the United ( printed page 18184) States; and granting preferential treatment to those companies that commit to onshore production of pharmaceuticals and pharmaceutical ingredients. 5. After considering the Secretary's report, the factors in section 232(d) ( 19 U.S.C. 1862(d) ), and other relevant factors and information, among other things, I concur with the Secretary's finding that pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States. In my judgment, and in light of the Secretary's report, the factors in section 232(d) ( 19 U.S.C. 1862(d) ), and other relevant factors and information, I have also determined that it is necessary and appropriate to adopt a plan of action, as described below, to adjust such imports of pharmaceuticals and associated pharmaceutical ingredients so that such imports will not threaten to impair the national security of the United States. 6. I have decided to direct the Secretary and the Secretary of Health and Human Services to pursue negotiations of agreements or continue any current negotiations of agreements, such as agreements contemplated in section 232(c)(3)(A)(i) ( 19 U.S.C. 1862(c)(3)(A)(i) ), to address the threatened impairment of the national security with respect to imported patented pharmaceuticals and associated pharmaceutical ingredients, with any party the Secretary and the Secretary of Health and Human Services deem appropriate, and to update me
The excerpt is reproduced from the public federal record and may omit later sections, tables, signatures or attachments. Open the official source for the complete text.
Questions for accountability
- Which products, countries and tariff rates were affected?
- Who legally pays the duty and how were costs distributed?
- Did later orders, courts or negotiations change the policy?
How to use this page
This is a source-record entry, not a truth-rating by itself. It preserves the action, date and original government publication so it can be connected to later claims, implementation records, court decisions, costs and measurable outcomes. Editorial claim reviews on this site use separate finding labels and explain the evidence for those findings.